Holmusk has filed a notice of an exempt offering of securities to raise $29,999,978.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Holmusk is raising $29,999,978.00 in new funding. Sources indicate that as part of senior management President, Tramontin David played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Holmusk
Holmusk is a data analytics and health technology company on a mission to harness real-world evidence to transform both research and care for behavioral health. Combining a leading behavioral health database with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusks core offerings include HolCare EHR+, an electronic health records platform with built-in measurement-based care, and NeuroBlu Research, a powerful data analytics solution that enables users to build patient cohorts, explore datasets, and discover new insights. Founded in 2015, Holmusk is a global company headquartered in Singapore and New York. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum.
To learn more about Holmusk, visit http://www.holmusk.com/
Contact:
Tramontin David, President
917-776-3057
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.